Abacavir: pretreatment screening: warning. Encouraging method but uncertainties remain.
HIV-infected patients carrying the HLA-B*5701 allele are at a significantly increased risk of developing hypersensitivity reactions to abacavir. It is therefore a good idea to identify these patients before initiating treatment. But even when patients test negative, hypersensitivity reactions are possible.
D000075202:Contraindications; D015224:Dideoxynucleosides / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D005602:France; D005820:Genetic Testing; D015658:HIV Infections / Q000188:drug therapy*; D015235:HLA-B Antigens / Q000235:genetics / Q000276:immunology; D006801:Humans; D006967:Hypersensitivity / Q000235:genetics*
D015224:Dideoxynucleosides; D015235:HLA-B Antigens